NAGA ABHINAY PASAM

Responsible for identifying the customers/doctors and driving customer engagement activities, market development initiatives such as Project Catalyst, Go Direct, KAM. Expanding the business in the assigned portfolio by devising go‑to‑market strategies and consistently improving the profitability of the company. Maintain and expand existing business and develop new business opportunities. Oversaw budget planning, strategy development, community outreach for organization. Improved overall efficiency by identifying areas in need of improvement and implementing necessary changes.

• Achieved 88%, Hyderabad 2024 & Achieved 100% & 90 % H1&H2 Vijayawada 2024
• On boarded 8 new accounts in Hyderabad in 6 months and subsequent revenues.
• On boarded 2 new accounts in Vijayawada in 2 months and subsequent revenues.
• After taking over Andhra Pradesh in June 2023, resolved the pending issues and customer complaints in that geography which had a significant impact on the business.
• Launched 2 new products into the market and their subsequent revenues
• Closed a long awaited deal in Andhra Pradesh in 1 month on January 2024, which was pending for an year and their subsequent revenues

Zimmer Biomet is 3rd largest Orthopedic implant company in the world. Identifying new streams for long‑term revenue growth, Designing strategies to mitigate non‑profitable geographies and enhance business in the profitable geographies. Developing & implementing long & medium‑term corporate strategies & business plans. Preoperative planning and selection of Orthopedic devices and logistics

• Achieved 94% , 98%, 100% budgets for the years 2022, 2021 & 2020 respectively, Andhra Pradesh.
• Re‑established Revision portfolios like LCCK, RHK, Continuum, Wagner SL
• Brought down DSO from 150 days to 98 days, which had a significant impact on the Business Profitability On‑boarded a strong working channel partner‑ Andhra Pradesh.
• Introduced Persona Knee System to the Market and subsequent revenues.

Johnson & Johnson is a 3rd largest pharmaceutical company in the world

• Achieved 106% and entered prestigious platform WINENRS CLUD for the year 2016 35% secondary growth in 2017 Increased sales by 20% over a period of three‑year
• 35% secondary growth in 2017
• Increased sales by 20% over a period of three‑year

• Promoted the Therapy Management in treating Diabetes
• Executed various cross‑functional activities like marketing, sales, target

• Successfully conducted various patient awareness camps, KOL meets, Offered the Therapy Management in treatment options with the drugs like Albendazole, Terbutaline, Neomycin
• Executed various cross‑functional activities like marketing, sales, target achievement, KPI, Non‑KPI